Rutin Therapy Reduces Ulcerative Colitis Disease Activity By Inhibiting The NOD-Like Receptor Protein 3 (NLRP3) Inflammasome: A Molecular Assessment in a Case-Control Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Success Rate of Treatment Regimens in improving the ulcerative colitis.
研究概览
简要总结
Ulcerative colitis (UC) is an inflammatory bowel disease characterized by oxidative stress and recurring inflammation in the colon. The condition can become chronic, spread, and lead to other complications.
A key player in the inflammation process is the NLRP3 inflammasome. This inflammasome's expression is heightened and activated by reactive oxygen species (ROS). Its activity is influenced by various factors, including the ubiquitin system, ion channels, and gut microbiota.
Rutin, a compound found in many fruits and vegetables, has been shown to have properties that help scavenge free radicals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients presenting with symptoms suggestive of IBD;
- •Patients with positive microscopic mucosal changes consistent with UC.
排除标准
- •Patients with the presence of recurrent ulceration after surgical treatment, malignancy, or autoimmune disorders.
研究组 & 干预措施
Ulcerative Colitis-B (UC-B)
Patients diagnosed with remission Ulcerative Colitis were assigned as control group UC-B
干预措施: fecal calprotectin (Diagnostic Test)
Ulcerative Colitis-A (UC-A)
Patients diagnosed with active Ulcerative Colitis were assigned as group UC-A
干预措施: Rutin 500 MG (Drug)
Ulcerative Colitis-A (UC-A)
Patients diagnosed with active Ulcerative Colitis were assigned as group UC-A
干预措施: fecal calprotectin (Diagnostic Test)
Ulcerative Colitis-B (UC-B)
Patients diagnosed with remission Ulcerative Colitis were assigned as control group UC-B
干预措施: Placebo (Other)
Healthy Group (C)
Healthy volunteers provided samples as negative controls; and was assigned as group C
干预措施: fecal calprotectin (Diagnostic Test)
结局指标
主要结局
Success Rate of Treatment Regimens in improving the ulcerative colitis.
时间窗: 3~4 Months
The proportion of patients who achieved a Simple Clinical Colitis Activity Index (SCCAI) score of 5 or less at the end of the study, which reflects the effectiveness of the treatment.
次要结局
未报告次要终点
研究者
Afnan El Gindy
Lecturer of Physiology, Faculty of Medicine
Benha University